Ankur Drugs and Pharma, formerly the Mridol Pharmaceuticals Limited was incorporated on February 9, 1995 with the Registrar of Companies, Maharashtra at Mumbai and a certificate of commencement of business was obtained on 7 March 1995. The Company was promoted by Shri Sandeep Parwal and Shri Harinarayan Attal. The company came up with a Public Issue of 57,00,000 Equity shares of Rs.10 each for cash at par opened for subscription in 1996 and the issue was oversubscribed.
The
Ankur Drugs and Pharma, formerly the Mridol Pharmaceuticals Limited was incorporated on February 9, 1995 with the Registrar of Companies, Maharashtra at Mumbai and a certificate of commencement of business was obtained on 7 March 1995. The Company was promoted by Shri Sandeep Parwal and Shri Harinarayan Attal. The company came up with a Public Issue of 57,00,000 Equity shares of Rs.10 each for cash at par opened for subscription in 1996 and the issue was oversubscribed.
The name of the company was changed from Mridol Pharmaceuticals Limited to Ankur Drugs and Pharma Limited in 1998.
Currently Ankur manufactures 400 different formulations for different dosage forms - viz Tablets, Capsules, Dry syrups, Liquid Orals,etc. Right from inception, Ankur has remained focused on its core business of Contract manufacturing. Since the last six years the company has not diluted it’s equity base. Ankur's debt level appears high primarily because of “Expansion for Growthâ€. Ankur has used its debts mostly to fund the core business expansion at Baddi by creating production facility for “best in worldâ€. Currently company operates in the ratio of 40% Loan License and 60% Third Party which it proposes to be 50:50 in coming future. Looking at the current business model company’s basic strategy is to approach big domestic players for contract manufacturing in formulations and maintain a sustainable net margin of 10% in their overall business. The company is targeting to grow multifold in coming years through contract manufacturing.
The company has recently announced that it will invest in the entire paid up share capital of TVC Life Sciences Ltd. in order to make it its wholly owned subsidiary. The group is engaged in manufacturing of pharma formulation in various dosage forms for leading Indian Companies. It is into 100% Contract Manufacturing activity and the plants are strategically located offering varied financial advantages to its customers.
Products:
ADPL is currently manufacturing brands like Mox, Cifran, Sporidex, Romilast, Fenak Plus, Omesec-20, Stanhist, Secafe, etc
Clientele:
- Ranbaxy Laboratories Limited
- Cipla Limited
- Khandelwal Laboratories Pvt. Limited
- Makers Laboratories Limited
- Hetero Healthcare Limited
- Elder Pharma Limited
- Lyka Labs Limited
- Blue Cross Laboratories Limited
- Cadila Laboratories Limited
- Wockhardt Limited
- Glenmark Pharma Limited
- Parentral Drugs (India) Limited
- Torrent Pharmaceuticals Limited
- Sandoz (India) pvt Limited
- Shreya Life Sicences Pvt. Limited
- Synthiko Formulations
- Nicholas Piramal India Limited
The company is planning for various international approvals mainly the US FDA and EU MHRA for the Baddi Plant which would help the company to start export business.
